Journal of travel medicine
-
What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective.
Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.
-
We present clinical, genomic and epidemiological data on the first 106 cases with the SARS-CoV-2 B.1.1.7 variant in Madrid. Even from the start, the increase of this variant was due to transmission events within the community, some causing extensive clusters, rather than further imports. Most cases developed non-severe disease.
-
Updated seroprevalence studies of infections in migrants may aid the design of tailored vaccination and prevention programmes. The objective of this study was to describe the seroprevalence rates for potentially transmissible viral infections in migrants attended at a referral centre in a major European city. ⋯ Differences in seroprevalence for vaccine-preventable and transmissible infections according to gender, age range and area of origin were observed. Tailored screening, vaccination and prevention strategies in potentially vulnerable migrant groups should be designed.